Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Arch Gynecol Obstet. 2021 Oct;304(4):1007-1020. doi: 10.1007/s00404-021-05997-w. Epub 2021 Feb 26.
Patients with lung metastases (LM) from epithelial ovarian cancer (EOC) (EOCLM) usually have a poor prognosis. However, there is no consensus on the optimal management of these patients. In this study, we aimed to take a look at the incidence of LM and factors associated with its occurrence as well as the prognosis in newly diagnosed EOC with LM on a population level.
EOC patients diagnosed between the years 2010 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) program database. Multivariable logistic regression and multivariable Cox regression were used to investigate the factors that could predict the occurrence of and prognosis after diagnosis of EOC with LM.
Of the 33,418 qualified EOC patients, 2240 (6.7%) were noted to have LMs at the time of EOC diagnosis. Higher T stage, N1 stage, advanced tumor grade, and elevated cancer antigen-125 levels were found to be associated with a higher risk of having LM at the time of EOC diagnosis. The median survival time after diagnosis with EOCLM was found to be 13.0 months (interquartile range: 3.0-34.0 months). Being unmarried and having mucinous histology were both associated with increased all-cause death risk from EOCLM. However, the primary tumor originated from the midline of ovaries, surgical management, and whether patient received chemotherapy or not predicted improved overall survival. The median survival time of patients was significantly longer for EOCLM cases managed surgically (31.0 months) versus those who did not have surgery (4.0 months), as well as EOCLM cases received chemotherapy (23.0 months) versus those who did not have chemotherapy (2.0 months).
This retrospective cohort study showed that de novo LM was infrequent in EOC patients overall and when present predicted poor prognosis. The findings can be potentially useful in formulating for follow-up strategies, screening tools, and personalized interventions.
患有上皮性卵巢癌(EOC)肺转移(LM)的患者通常预后较差。然而,对于这些患者的最佳治疗方法尚无共识。本研究旨在从人群水平上观察 LM 的发生率、与 LM 发生相关的因素以及新诊断为 LM 的 EOC 的预后。
从监测、流行病学和最终结果(SEER)计划数据库中确定了 2010 年至 2016 年期间诊断的 EOC 患者。采用多变量逻辑回归和多变量 Cox 回归分析预测 EOC 合并 LM 患者的发生和预后的因素。
在 33418 名合格的 EOC 患者中,2240 名(6.7%)在 EOC 诊断时发现有 LM。较高的 T 分期、N1 分期、高级别肿瘤、升高的癌抗原 125 水平与 EOC 诊断时发生 LM 的风险较高相关。诊断为 EOCLM 后的中位生存时间为 13.0 个月(四分位距:3.0-34.0 个月)。未婚和黏液组织学均与 EOCLM 的全因死亡风险增加相关。然而,原发肿瘤位于卵巢中线、手术治疗以及患者是否接受化疗均预测了总体生存率的提高。接受手术治疗的 EOCLM 患者(31.0 个月)的中位生存时间明显长于未接受手术治疗的患者(4.0 个月),接受化疗的 EOCLM 患者(23.0 个月)的中位生存时间明显长于未接受化疗的患者(2.0 个月)。
这项回顾性队列研究表明,EOC 患者总体上新发性 LM 并不常见,且存在 LM 时预测预后不良。这些发现可能有助于制定随访策略、筛查工具和个性化干预措施。